An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 471 participants.
Also called NCT01560637
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 471 participants
- Sponsor
- Registry
-
NCT01560637
-
- Other papers using this trial's data
- Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Denmark, France, Germany, Greece, India, Israel, Italy, Mexico, Netherlands, Poland, Singapore, South Korea, Sweden, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01560637. Allocation not applicable; no masking; primary purpose treatment. Start 2013-09-11 (actual); primary completion 2021-08-12 (actual). Results posted on 2022-06-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- UT-15C (treprostinil diolamine)
- Lead sponsor
- United Therapeutics
Record details
- Record id
cardio:ct-nct01560637- Content hash
b30a07517fbd221366b48e57c350dccf0815b5a6b19a5fcbe256c9a8b6032dfc